# US 2019/0167854 A1 · Drug coated balloon catheters for nonvascular strictures

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167854 A1
- Document ID: US20190167854A1
- Status: Published application
- Kind: A1
- Application number: 16/267,434
- Filed: 2019-02-05
- Published: 2019-06-06
- Earliest claimed: 2012-10-26
- Assignees: Urotronic, Inc.
- Applicants: Urotronic, Inc.
- Inventors: Lixiao Wang
- Web page: https://patentgrep.com/patent/US20190167854A1

## CPC

- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61L 29/08: Materials for coatings
- A61L 29/085: {Macromolecular materials}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/08: of the prostate
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61L 2300/41: Anti-inflammatory agents, e.g. NSAIDs
- A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A61L 2300/45: Mixtures of two or more drugs, e.g. synergistic mixtures
- A61L 2300/602: Type of release, e.g. controlled, sustained, slow
- A61L 2300/606: Coatings
- A61L 2300/802: Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
- A61L 2420/06: Coatings containing a mixture of two or more compounds
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Embodiments of the present invention provide a method for treatment of nonvascular body lumen strictures such as benign prostatic hyperplasia (BPH), urethral strictures, ureteral strictures, prostate cancer, esophageal strictures, sinus strictures, biliary tract strictures, asthma and chronic obstructive pulmonary disease (COPD). The method involves delivering, preferably via drug coated balloon catheters, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues) and one or more additives.

## Claims

### Claim 1

A method for treating sinusitis, a sinus stricture, or a nasal lumen, the method comprising:
inserting a balloon catheter into a target site, wherein the target site is the sinus stricture or the nasal lumen, the balloon catheter comprising
a coating layer overlying an exterior surface of a balloon that is inflatably expandable, the coating layer comprising
an initial drug load comprising mometasone furoate, wherein the initial drug load has a density of the mometasone furoate in the coating layer of 1 to 20 μg per mm2 of the exterior surface of the balloon, and
an additive;
inflating the balloon at least until the coating layer contacts walls of the target site to transfer at least some of the coating layer to the walls of the target site;
deflating the balloon; and
withdrawing the balloon catheter from the target site.

### Claim 2 (depends on 1)

The method of claim 1, wherein the coating layer contacts the walls of the target site for an inflation period that is from 0.1 minutes to 30 minutes.

### Claim 3 (depends on 1)

The method of claim 1, wherein after the withdrawing of the balloon catheter from the target site the balloon has thereon a residual drug amount that is less than 45% of the initial drug load.

### Claim 4 (depends on 1)

The method of claim 1, wherein during the transferring of the coating layer to the walls of the target site, the coating layer makes uniform direct pressure contact with the walls of the target site.

### Claim 5 (depends on 1)

The method of claim 1, wherein the mometasone furoate is a crystal form of mometasone furoate.

### Claim 6 (depends on 1)

The method of claim 1, wherein the additive comprises an excipient, a natural product or derivative thereof, an oligomer, a surfactant, or a combination thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the additive comprises a polysorbate, polyethylene glycol, polypropylene glycol, polyvinyl pyrrolidinone, a glycerol fatty acid ester, a fatty acid, a poloxamer, 2-hydroxypropyl cyclodextrin, sucrose monopalmitate, sucrose monolaurate, glycerol, an alcohol, a propylene glycol fatty acid ester, cellulose, polycaprolactone, a polyester, a polyurethane, a polylactic acid-polyethylene oxide copolymer, or a combination thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the additive comprises a polysorbate, polyethylene glycol, polyvinyl pyrrolidinone, a glycerol fatty acid ester, or a combination thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the additive comprises polyvinyl pyrrolidone.

### Claim 10 (depends on 1)

The method of claim 1, wherein the additive comprises a polysorbate.

### Claim 11 (depends on 10)

The method of claim 10, wherein the polysorbate is a PEG sorbitan fatty ester, a PEG sorbitan monolaurate, a PEG sorbitan monopalmitate, a PEG sorbitan monooleate, a PEG sorbitan monostearate, PEG-20 sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monooleate, PEG-20 sorbitan monostearate, or a combination thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the additive comprises a glycerol fatty acid ester.

### Claim 13 (depends on 1)

The method of claim 1, wherein the additive comprises a polysorbate and polyethylene glycol.

### Claim 14 (depends on 1)

The method of claim 1, wherein a ratio of the additive to the initial drug load in the coating layer by weight is 20:1 to 0.05:1.

### Claim 15 (depends on 1)

The method of claim 1, wherein a ratio of the additive to the initial drug load in the coating layer by weight is 10:1 to 0.5:1

### Claim 16 (depends on 1)

The method of claim 1, wherein the ratio of the additive to the initial drug load in the coating layer by weight is 5:1 to 0.8:1.

### Claim 17 (depends on 1)

The method of claim 1, wherein the initial drug load has a density of the mometasone furoate in the coating layer of 2 to 10 μg per mm2 of the exterior surface of the balloon.

### Claim 18 (depends on 1)

The method of claim 1, wherein the initial drug load has a density of the mometasone furoate in the coating layer of 2 to 6 μg per mm2 of the exterior surface of the balloon.

### Claim 19 (depends on 1)

The method of claim 1, wherein the coating layer has a uniform thickness.

### Claim 20 (depends on 1)

The method of claim 1, wherein the balloon has a uniform circular cross-section perpendicular to a longitudinal direction of the balloon.

### Claim 21 (depends on 1)

The method of claim 1, wherein the mometasone furoate is the only drug in the balloon catheter.

### Claim 22 (depends on 1)

The method of claim 1, wherein the initial drug load consists of the mometasone furoate.
